Trial intelligence / Profile preview

Long-term ovarian function after ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in fertile women with chronic hepatitis C

2016-003607-59Phase 4Terminated

Sponsor
DIPARTIMENTO AD ATTIVITÃ INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE
Start
Jun 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 4 trial of paritaprevir, dasabuvir, ribavirin in chronic hepatitis C (CHC), sponsored by DIPARTIMENTO AD ATTIVITÃ INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE. Started Jun 2021; status: terminated.

02

Drugs

paritaprevirdasabuvirribavirin
03

Conditions

chronic hepatitis C (CHC)

Beyond the preview

Go deeper on 2016-003607-59.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-003607-59.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call